Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of 0.78 is 254% above its 5-year average of -0.51, near the high end of its 5-year range (-0.86–0.78).
383.64% above its 12-month average of -0.28.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.03.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T16:30:49.519Z. Historical observations retain their original dates. Historical series through 2026-10-05.
EARNINGS PER SHARE (EPS)
0.78
EARNINGS PER SHARE (EPS) AVG TTM
-0.28
EARNINGS PER SHARE (EPS) AVG 3Y
-0.36
EARNINGS PER SHARE (EPS) AVG 5Y
-0.51
EARNINGS PER SHARE (EPS) AVG 10Y
-1.53
EARNINGS PER SHARE (EPS) AVG 15Y
-1.03
EARNINGS PER SHARE (EPS) AVG 20Y
-0.92
CURRENT VS TTM AVG
+383.64%
CURRENT VS 3Y AVG
+315.17%
CURRENT VS 5Y AVG
+253.95%
CURRENT VS 10Y AVG
+150.83%
CURRENT VS 15Y AVG
+175.73%
CURRENT VS 20Y AVG
+184.73%
Arbutus Biopharma Corp
Market Cap
$888.92M
Earnings Per Share (EPS)
0.78
TTM Avg
-0.28
3Y Avg
-0.36
5Y Avg
-0.51
Market Cap
$901.73M
Earnings Per Share (EPS)
0.77
TTM Avg
-0.09
3Y Avg
-1.31
5Y Avg
-0.73
Market Cap
$879.59M
Earnings Per Share (EPS)
-0.64
TTM Avg
-0.60
3Y Avg
-0.67
5Y Avg
-0.65
Market Cap
$872.19M
Earnings Per Share (EPS)
16.32
TTM Avg
10.69
3Y Avg
4.14
5Y Avg
2.27
Market Cap
$916.63M
Earnings Per Share (EPS)
0.72
TTM Avg
0.64
3Y Avg
0.54
5Y Avg
0.47
Market Cap
$865.70M
Earnings Per Share (EPS)
-0.34
TTM Avg
-0.59
3Y Avg
-1.03
5Y Avg
-1.22
Market Cap
$857.96M
Earnings Per Share (EPS)
N/A
TTM Avg
0.00
3Y Avg
0.00
5Y Avg
0.00
Market Cap
$845.57M
Earnings Per Share (EPS)
-15.44
TTM Avg
-23.62
3Y Avg
-9.43
5Y Avg
-0.29
Market Cap
$933.39M
Earnings Per Share (EPS)
-1.76
TTM Avg
-1.29
3Y Avg
-1.36
5Y Avg
-1.36
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $888.92M | 0.78 | -0.28 | -0.36 | -0.51 |
| Bioventus Inc. (BVS)vs › | $901.73M | 0.77 | -0.09 | -1.31 | -0.73 |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $879.59M | -0.64 | -0.60 | -0.67 | -0.65 |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $872.19M | 16.32 | 10.69 | 4.14 | 2.27 |
| HealthStream, Inc. (HSTM)vs › | $916.63M | 0.72 | 0.64 | 0.54 | 0.47 |
| SI-BONE, Inc. (SIBN)vs › | $865.70M | -0.34 | -0.59 | -1.03 | -1.22 |
| SL Science Holding Ltd (SLBT)vs › | $857.96M | N/A | 0.00 | 0.00 | 0.00 |
| QuidelOrtho Corporation (QDEL)vs › | $845.57M | -15.44 | -23.62 | -9.43 | -0.29 |
| CeriBell, Inc. (CBLL)vs › | $933.39M | -1.76 | -1.29 | -1.36 | -1.36 |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $849.02M | -2.18 | -0.78 | -1.63 | -1.49 |
Trailing EPS (TTM)
$0.78
Forward EPS (Est.)
$0.74
P/E Ratio
5.8
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.17 |
| 2024-12-31 | -0.38 |
| 2023-12-31 | -0.44 |
| 2022-12-31 | -0.46 |
| 2021-12-31 | -0.73 |
| 2020-12-31 | -0.86 |
| 2019-12-31 | -2.69 |
| 2018-12-31 | -1.03 |
| 2017-12-31 | -1.54 |
| 2016-12-31 | -7.24 |
| 2015-12-31 | -1.34 |
| 2014-12-31 | -1.80 |
| 2013-12-31 | -0.92 |
| 2012-12-31 | 2.16 |
| 2011-12-31 | -0.86 |
| 2010-12-31 | -1.20 |
| 2009-12-31 | -0.90 |
| 2008-12-31 | -1.44 |
| 2007-12-31 | -0.54 |
| 2006-12-31 | 4.68 |
| 2005-12-31 | -1.04 |
| 2004-12-31 | -3.64 |
| 2003-12-31 | -4.78 |
| 2002-12-31 | -4.08 |
| 2001-12-31 | -2.76 |
| 2000-12-31 | -1.87 |
| 1999-12-31 | -2.90 |
| 1998-12-31 | -4.05 |
